Vistagen Therapeutics Inc (VTGN) advances its fasodinol program with promising trial updates and strategic board appointments ...

Vistagen Therapeutics Inc. (($VTGN)) has held its Q2 earnings call. Read on for the main highlights of the call. Vistagen Therapeutics Inc.

Detailed price information for Vistagen Therapeutics Inc (VTGN-Q) from The Globe and Mail including charting and trades.

Analysts expect VistaGen Therapeutics to report an earnings per share (EPS) of $-0.47. VistaGen Therapeutics bulls will hope ...

VistaGen Therapeutics VTGN is gearing up to announce its quarterly earnings on Thursday, 2025-08-07. Here's a quick overview of what investors should know before the release. Analysts are estimating ...

Michelle Peters Wellington announced Thursday that she has joined Vistagen Therapeutics as VP of communications. Wellington is a comms veteran, having held leadership posts at SKDK, Sloane & Company ...

VistaGen Therapeutics is developing CNS drugs for anxiety, depression, and other disorders, with Fasedienol in phase 3 clinical trials. Fasedienol has advantages as a non-systemic, low-abuse ...

SOUTH SAN FRANCISCO, CA--(Marketwire - Oct 16, 2012) - VistaGen Therapeutics, Inc. (OTCBB: VSTA) (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue and novel ...

VistaGen Therapeutics, Inc. (VTGN) came out with a quarterly loss of $0.47 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.35 per share a year ago. These figures are ...

VistaGen Therapeutics, Inc. (VTGN) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to a loss of $0.42 per share a year ago.